Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Forbion Capital Fund IV Cooperatief U.A. - 31 Mar 2025 SCHEDULE 13G/A Report for Dyne Therapeutics, Inc. Common Stock, par value $0.0001 (DYN)
- Filing manager
- Forbion Capital Fund IV Cooperatief U.A.
- Reporting owner
- ForDyne B.V.
- Beneficially owned shares
- 5,400,545 shares
- Large-stake signal
-
Ownership
4.8%Beneficial ownership of this reported class.
Shares
5,400,545 sharesShares beneficially owned as disclosed.
Event date
31 Mar 2025Date tied to the ownership event or amendment.
Accepted by SEC
15 May 2025EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 4.8%
- Symbol
- DYN
- Shares outstanding
- 112,511,354 shares
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 15 May 2025, 08:46:56 UTC
- Event date
- 31 Mar 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
2 source fields
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Forbion Capital Fund IV Cooperatief U.A. disclosed 4.8% ownership in Dyne Therapeutics, Inc. Common Stock, par value $0.0001 (DYN) on 31 Mar 2025.
Key facts
- Forbion Capital Fund IV Cooperatief U.A. filed SCHEDULE 13G/A for Dyne Therapeutics, Inc. Common Stock, par value $0.0001 (DYN).
- Disclosed ownership: 4.8%.
- Date of event: 31 Mar 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2025, 08:46.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (5)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| ForDyne B.V. | 4.8% | 5,400,545 | 0 | 5,400,545 | /s/ V. van Houten /s/ H.A. Slootweg | V. van Houten and H.A. Slootweg, Directors of its Director | |
| Forbion Capital Fund IV Cooperatief U.A. | 3.6% | 4,036,476 | 0 | 4,036,476 | /s/ V. van Houten /s/ H.A. Slootweg | V. van Houten and H.A. Slootweg, Directors of its Director | |
| Forbion IV Management B.V. | 3.6% | 4,036,476 | 0 | 4,036,476 | /s/ V. van Houten /s/ H.A. Slootweg | V. van Houten and H.A. Slootweg, Directors of its Director | |
| Forbion Growth Opportunities Fund II Cooperatief U.A. | 1.3% | 1,426,370 | 0 | 1,426,370 | /s/ V. van Houten /s/ H.A. Slootweg | V. van Houten and H.A. Slootweg, Directors | |
| Forbion Growth II Management B.V. | 1.3% | 1,426,370 | 0 | 1,426,370 | /s/ V. van Houten /s/ H.A. Slootweg | V. van Houten and H.A. Slootweg, Directors |
CIK / CUSIP context first